Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials

Deng, Manjun; Wen, Yonghao; Yan, JingXin; Fan, Yichen; Wang, Zhixin; Zhang, Ruixia; Ren, Li; Ba, Yinggui; Wang, Haijiu; Lu, Qian; Fan, Haining

doi:10.1186/s12916-023-03129-6

Table 1 Baseline characteristics of included studies

From: Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials

Author	Year	Region	Race	Follow-up	Number of patients	Intervention	BMI of baseline (mean)	Glycated haemoglobin of baseline	Diet control and exercise
Fan, H [49]	2013	Beijing, China	Asian	12 weeks	Group 1: 49	Group 1: Exenatide 20 μg/d	Group 1: 28.18	7–9%	Yes
Fan, H [49]	2013	Beijing, China	Asian	12 weeks	Group 2: 68	Group 2: Metformin 1 g/d	Group 2: 27.61	7–9%	Yes
Dasarathy, S [50]	2015	America	Caucasian	48 weeks	Group 1: 18	Group 1: Omega 3 3.6 g/d	Group 1: 34.8	< 8.5%	Yes
Dasarathy, S [50]	2015	America	Caucasian	48 weeks	Group 2: 19	Group 2: Standard treatment	Group 2: 35.7	< 8.5%	Yes
Feng, W [68]	2017	Nanjing, China	Asian	24 weeks	Group 1: 29	Group 1: Liraglutide 1.8 mg/d	Group 1: 28.12	7–14%	Yes
					Group 2: 29	Group 2: Gliclazide 30–120 mg/d	Group 2: 27.85
					Group 3: 29	Group 3: Metformin 2 g/d	Group 3: 26.82
Ito, D [51]	2017	Saitama, Japan	Asian	24 weeks	Group 1: 34	Group 1: Pioglitazone 15 or 30 mg/d	Group 1: 29.9	7–11%	No
Ito, D [51]	2017	Saitama, Japan	Asian	24 weeks	Group 2: 32	Group 2: Ipragliflozin 50 mg/d	Group 2: 30.7	7–11%	No
Eriksson, JW [53]	2018	Sweden	Caucasian	12 weeks	Group 1: 19	Group 1: Standard treatment	Group 1: 30.3	NA	No
					Group 2: 15	Group 2: Omega 3 4 g/d	Group 2: 33.0
					Group 3: 19	Group 3: Dapagliflozin 10 mg/d	Group 3: 30.5
Shimizu, M [54]	2019	America	Hispanic	24 weeks	Group 1: 33	Group 1: Dapagliflozin 5 mg/d	Group 1: 27.6	6–12%	No
Shimizu, M [54]	2019	America	Hispanic	24 weeks	Group 2: 24	Group 2: Standard treatment	Group 2: 28.7	6–12%	No
Feng, W H [55]	2019	China	Asian	24 weeks	Group 1: 29	Group 1: Liraglutide 1.8 mg/d	Group 1: 28.1	7–14%	Yes
					Group 2: 29	Group 2: Metformin 2 g/d	Group 2: 26.8
					Group 3: 27	Group 3: Gliclazide 30–120 mg/d	Group 3: 27.5
Aso, Y [69]	2019	Japan	Asian	24 weeks	Group 1: 33	Group 1: Dapagliflozin 5 mg/d	Group 1: 27.6	6–12%	No
Aso, Y [69]	2019	Japan	Asian	24 weeks	Group 2: 24	Group 2: Standard treatment	Group 2: 28.7	6–12%	No
Liu, L [56]	2020	Shanghai, China	Asian	24 weeks	Group 1: 35	Group 1: Exenatide 20 μg/d	Group 1: 28.49	7–10%	No
Liu, L [56]	2020	Shanghai, China	Asian	24 weeks	Group 2: 36	Group 2: Insulin glargine 0.1–0.3 IU/kg	Group 2: 27.84	7–10%	No
Zhang, L Y[57]	2020	Hispanic	Asian	24 weeks	Group 1: 30	Group 1: Liraglutide 1.2 mg/d	Group 1: 27.6	7–14%	Yes
Zhang, L Y[57]	2020	Hispanic	Asian	24 weeks	Group 2: 30	Group 2: Pioglitazone 30 mg/d	Group 2: 27.1	7–14%	Yes
Kinoshita, T [59]	2020	Japan	Asian	28 weeks	Group 1: 33	Group 1: Pioglitazone 7.5–15 mg/d	Group 1: 28.7	≥ 6.5%	No
					Group 2: 32	Group 2: Dapagliflozin 5 mg/d	Group 2: 29.5
					Group 3: 33	Group 2: Glimepiride 0.5– 1 mg/d	Group 3: 28.4
Guo, W [60]	2020	Fujian, China	Asian	26 weeks	Group 1: 30	Group 1: Insulin glargine 10 IU/d	Group 1: 28.3	≥ 6.5%	Yes
					Group 2: 31	Group 2: Liraglutide 1.8 mg/d	Group 2: 29.2
					Group 3: 30	Group 3: Metformin	Group 3: 28.6
Sangouni, AA [61]	2021	Yazd, Iran	Asian	12 weeks	Group 1: 28	Group 1: Omega 3 2 g/d	Group 1: 30.26	NA	Yes
Sangouni, AA [61]	2021	Yazd, Iran	Asian	12 weeks	Group 2: 28	Group 2: Metformin	Group 2: 29.8	NA	Yes
Tian, F [63]	2018	China	Asian	12 weeks	Group 1: 52	Group 1: Liraglutide 0.6–1.2 mg/d	Group 1: 28.18	< 9%	Yes
Tian, F [63]	2018	China	Asian	12 weeks	Group 2: 75	Group 2: Metformin 1–1.5 g/d	Group 2: 27.61	< 9%	Yes
Bando, Y [70]	2017	Japan	Asian	12 weeks	Group 1: 40	Group 1: Ipragliflozin 50 mg/d	Group 1: 27.8	7–10%	Yes
Bando, Y [70]	2017	Japan	Asian	12 weeks	Group 2: 22	Group 2: Standard treatment	Group 2: 27.3	7–10%	Yes
Cho, K Y [71]	2021	Japan	Asian	24 weeks	Group 1: 27	Group 1: Dapagliflozin 5 mg/d	NA	6.5–8.5%	No
Cho, K Y [71]	2021	Japan	Asian	24 weeks	Group 2: 26	Group 2: Pioglitazone 30 mg/d	NA	6.5–8.5%	No
Phrueksotsai, S [62]	2021	Thailand	Asian	12 weeks	Group 1: 18	Group 1: Dapagliflozin 10 mg/d	Group 1: 29.6	7–10%	No
Phrueksotsai, S [62]	2021	Thailand	Asian	12 weeks	Group 2: 20	Group 2: Standard treatment	Group 2: 28.8	7–10%	No
Kuchay, MS [52]	2018	India	Asian	20 weeks	Group 1: 20	Group 1: Standard treatment	Group 1: 29.4	7–10%	No
Kuchay, MS [52]	2018	India	Asian	20 weeks	Group 2: 22	Group 2: Empagliflozin10mg/d	Group 2: 30.0	7–10%	No
Chehrehgosha, H [72]	2021	Iran	Asian	24 weeks	Group 1: 37	Group 1: Standard treatment	Group 1: 30.2	7–10%	Yes
					Group 2: 35	Group 2: Empagliflozin 10 mg/d	Group 2: 30.9
					Group 3: 26	Group 3: Pioglitazone 30 mg/d	Group 3: 29.4
Deng, XL [67]	2017	China	Asian	26 weeks	Group 1: 36	Group 1: Sitagliptin 50 mg/d	Group 1: 24.1	NA	Yes
Deng, XL [67]	2017	China	Asian	26 weeks	Group 2: 36	Group 2: Standard treatment	Group 2: 23.9	NA	Yes
Yoneda, M [58]	2021	Japan	Asian	24 weeks	Group 1: 19	Group 1: Pioglitazone 15–30 mg/d	Group 1: 30.8	≥ 6.5%	Yes
Yoneda, M [58]	2021	Japan	Asian	24 weeks	Group 2: 21	Group 2: Tofogliflozin 20 mg/d	Group 2: 29.4	≥ 6.5%	Yes
Takeshita, Y [64]	2022	Japan	Asian	48 weeks	Group 1: 20	Group 1: Tofogliflozin 20 mg/d	Group 1: 31.0	7.3–8.8%	Yes
Takeshita, Y [64]	2022	Japan	Asian	48 weeks	Group 2: 20	Group 2: Glimepiride 0.5 mg/d	Group 2: 32.0	7.3–8.8%	Yes
Hiruma, S [65]	2023	Japan	Asian	12 weeks	Group 1: 23	Group 1: Empagliflozin10mg/d	Group 1: 30.6	< 10%	No
Hiruma, S [65]	2023	Japan	Asian	12 weeks	Group 2: 19	Group 2: Sitagliptin 100 mg/d	Group 2: 28.6	< 10%	No
Nar, A [66]	2009	Turkey	Caucasian	24 weeks	Group 1: 19	Group 1: Metformin 1.7 g/d	Group 1: 31.0	NA	Yes
Nar, A [66]	2009	Turkey	Caucasian	24 weeks	Group 2: 15	Group 2: Standard treatment	Group 2: 33.7	NA	Yes

Back to article page

ISSN: 1741-7015

Contact us

Submission enquiries: bmcmedicineeditorial@biomedcentral.com
General enquiries: info@biomedcentral.com

BMC Medicine

Contact us